These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30948360)

  • 21. Neurosurgical management of elevated tone in childhood: interventions, indications and uncertainties.
    Lumsden DE
    Arch Dis Child; 2023 Sep; 108(9):703-708. PubMed ID: 36690424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of intrathecal baclofen therapy in patients with cerebral palsy and acquired brain injury.
    Yoon YK; Lee KC; Cho HE; Chae M; Chang JW; Chang WS; Cho SR
    Medicine (Baltimore); 2017 Aug; 96(34):e7472. PubMed ID: 28834868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of botulinum toxin A in children with cerebral palsy.
    Ross Raftemo AE; Mahendran A; Hollung SJ; Jahnsen RB; Lydersen S; Vik T; Andersen GL
    Tidsskr Nor Laegeforen; 2019 May; 139(8):. PubMed ID: 31062563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapy of spasticity in children with cerebral palsy.
    Chung CY; Chen CL; Wong AM
    J Formos Med Assoc; 2011 Apr; 110(4):215-22. PubMed ID: 21540003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A French observational study of botulinum toxin use in the management of children with cerebral palsy: BOTULOSCOPE.
    Chaléat-Valayer E; Parratte B; Colin C; Denis A; Oudin S; Bérard C; Bernard JC; Bourg V; Deleplanque B; Dulieu I; Evrard P; Filipetti P; Flurin V; Gallien P; Héron-Long B; Hodgkinson I; Husson I; Jaisson-Hot I; Maupas E; Meurin F; Monnier G; Pérennou D; Pialoux B; Quentin V; Moreau MS; Schneider M; Yelnik A; Marque P
    Eur J Paediatr Neurol; 2011 Sep; 15(5):439-48. PubMed ID: 21745754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral Muscle Relaxants for the Treatment of Chronic Pain Associated with Cerebral Palsy.
    Peck J; Urits I; Crane J; McNally A; Noor N; Patel M; Berger AA; Cornett EM; Kassem H; Kaye AD; Viswanath O
    Psychopharmacol Bull; 2020 Oct; 50(4 Suppl 1):142-162. PubMed ID: 33633423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of spasticity].
    Autti-Rämö I
    Duodecim; 1999; 115(8):877-85. PubMed ID: 11859520
    [No Abstract]   [Full Text] [Related]  

  • 28. Intrathecal baclofen in the treatment of spasticity, dystonia and vegetative disorders.
    Richard I; Menei P
    Acta Neurochir Suppl; 2007; 97(Pt 1):213-8. PubMed ID: 17691379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. National surveillance of oral medication prescription for children with dystonic cerebral palsy.
    Harvey A; Bear N; Rice J; Antolovich G; Waugh MC
    J Paediatr Child Health; 2021 Aug; 57(8):1222-1227. PubMed ID: 33655652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Botulinum toxin type A in the treatment plan for cerebral palsy].
    Strobl W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():30-5. PubMed ID: 15506050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of intrathecal baclofen on muscle co-contraction in children with spasticity of cerebral origin.
    Sgouros S; Seri S
    Pediatr Neurosurg; 2002 Nov; 37(5):225-30. PubMed ID: 12411712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spasticity and movement disorders in cerebral palsy.
    Albright AL
    Childs Nerv Syst; 2023 Oct; 39(10):2877-2886. PubMed ID: 37410128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative study of therapeutic response to baclofen vs tolperisone in spasticity.
    Agarwal S; Patel T; Shah N; Patel BM
    Biomed Pharmacother; 2017 Mar; 87():628-635. PubMed ID: 28086137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin.
    Koman LA; Paterson Smith B; Balkrishnan R
    Paediatr Drugs; 2003; 5(1):11-23. PubMed ID: 12513103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Approach to the rehabilitation of spasticity and neuromuscular disorders in children.
    Tilton AH
    Neurol Clin; 2003 Nov; 21(4):853-81, vii. PubMed ID: 14743653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy.
    Wasiak J; Hoare B; Wallen M
    Cochrane Database Syst Rev; 2004 Oct; (4):CD003469. PubMed ID: 15495055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of continuous intrathecal baclofen infusion and selective posterior rhizotomy on upper extremity spasticity.
    Albright AL; Barry MJ; Fasick MP; Janosky J
    Pediatr Neurosurg; 1995; 23(2):82-5. PubMed ID: 8555100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Botulinum toxin in the management of spastic hip adductors in non-ambulatory cerebral palsy children].
    Deleplanque B; Lagueny A; Flurin V; Arnaud C; Pedespan JM; Fontan D; Pontallier JR
    Rev Chir Orthop Reparatrice Appar Mot; 2002 May; 88(3):279-85. PubMed ID: 12037484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative profile of tizanidine in the management of spasticity.
    Lataste X; Emre M; Davis C; Groves L
    Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical practices in intrathecal baclofen pump implantation in children with cerebral palsy in France.
    Mietton C; Nuti C; Dohin B; Bayle B; Fernandez B; Poirot I; Gautheron V; Vuillerot C
    Ann Phys Rehabil Med; 2016 Sep; 59(4):282-4. PubMed ID: 27158102
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.